Advice

in the absence of a submission from the holder of the marketing authorisation:

adalimumab (Humira®) is not recommended for use within NHS Scotland.

Indication under review: treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.
 

Download detailed advice77KB (PDF)

Download

Medicine details

Medicine name:
adalimumab (Humira)
SMC ID:
800/12
Indication:
Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Pharmaceutical company
Abbott Laboratories
BNF chapter
Gastro-intestinal system
Submission type
Non submission
Status
Superseded
Date advice published
09 July 2012
Additional notes

NICE MTA Advice: SMC Advice is superseded by National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal (MTA)